121 related articles for article (PubMed ID: 38311187)
1. Fexofenadine-loaded chitosan coated solid lipid nanoparticles (SLNs): A potential oral therapy for ulcerative colitis.
El-Dakroury WA; Zewail MB; Asaad GF; Abdallah HMI; Shabana ME; Said AR; Doghish AS; Azab HA; Amer DH; Hassan AE; Sayed AS; Samra GM; Sallam AM
Eur J Pharm Biopharm; 2024 Mar; 196():114205. PubMed ID: 38311187
[TBL] [Abstract][Full Text] [Related]
2. Eluxadoline Loaded Solid Lipid Nanoparticles for Improved Colon Targeting in Rat Model of Ulcerative Colitis.
Anwer MK; Ahmed MM; Aldawsari MF; Alshahrani S; Fatima F; Ansari MN; Rehman NU; Al-Shdefat RI
Pharmaceuticals (Basel); 2020 Sep; 13(9):. PubMed ID: 32961713
[TBL] [Abstract][Full Text] [Related]
3. Taurine loaded chitosan-pectin nanoparticle shows curative effect against acetic acid-induced colitis in rats.
Ahmed O; Abdel-Halim M; Farid A; Elamir A
Chem Biol Interact; 2022 Jan; 351():109715. PubMed ID: 34695389
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic effect of 5-ASA and hesperidin-loaded chitosan/Eudragit® S100 nanoparticles as a pH-sensitive carrier for local targeted drug delivery in a rat model of ulcerative colitis.
Abdollahy A; Salehi M; Mahami S; Bernkop-Schnürch A; Vahedi H; Gharravi AM; Mehrabi M
Int J Pharm; 2024 Mar; 652():123838. PubMed ID: 38266937
[TBL] [Abstract][Full Text] [Related]
5. Surface-anchored microbial enzyme-responsive solid lipid nanoparticles enabling colonic budesonide release for ulcerative colitis treatment.
Zhang Y; Wang L; Wang ZD; Zhou Q; Zhou X; Zhou T; Guan YX; Liu X
J Nanobiotechnology; 2023 May; 21(1):145. PubMed ID: 37127609
[TBL] [Abstract][Full Text] [Related]
6. Achillea wilhelmsii-Incorporated Chitosan@Eudragit Nanoparticles Intended for Enhanced Ulcerative Colitis Treatment.
Maleki H; Doostan M; Farzaei MH; Seifi P; Miraghaee S; Doostan M
AAPS PharmSciTech; 2023 Apr; 24(5):112. PubMed ID: 37118443
[TBL] [Abstract][Full Text] [Related]
7. Mucus-Penetrating Alginate-Chitosan Nanoparticles Loaded with Berberine Hydrochloride for Oral Delivery to the Inflammation Site of Ulcerative Colitis.
Sun L; Nie X; Lu W; Zhang Q; Fang W; Gao S; Chen S; Hu R
AAPS PharmSciTech; 2022 Jun; 23(6):179. PubMed ID: 35761150
[TBL] [Abstract][Full Text] [Related]
8. Design, characterization and in vivo performance of solid lipid nanoparticles (SLNs)-loaded mucoadhesive buccal tablets for efficient delivery of Lornoxicam in experimental inflammation.
Zewail MB; F Asaad G; Swellam SM; Abd-Allah SM; K Hosny S; Sallah SK; E Eissa J; S Mohamed S; El-Dakroury WA
Int J Pharm; 2022 Aug; 624():122006. PubMed ID: 35820515
[TBL] [Abstract][Full Text] [Related]
9. Mucoadhesive chitosan hydrogels as rectal drug delivery vessels to treat ulcerative colitis.
Xu J; Tam M; Samaei S; Lerouge S; Barralet J; Stevenson MM; Cerruti M
Acta Biomater; 2017 Jan; 48():247-257. PubMed ID: 27769943
[TBL] [Abstract][Full Text] [Related]
10. Mucoadhesive chitosan-coated solid lipid nanoparticles for better management of tuberculosis.
Vieira ACC; Chaves LL; Pinheiro S; Pinto S; Pinheiro M; Lima SC; Ferreira D; Sarmento B; Reis S
Int J Pharm; 2018 Jan; 536(1):478-485. PubMed ID: 29203137
[TBL] [Abstract][Full Text] [Related]
11. Physicochemical Characterization of Chitosan-Decorated Finasteride Solid Lipid Nanoparticles for Skin Drug Delivery.
Sohaib M; Shah SU; Shah KU; Shah KU; Khan NR; Irfan MM; Niazi ZR; Alqahtani AA; Alasiri A; Walbi IA; Mahmood S
Biomed Res Int; 2022; 2022():7792180. PubMed ID: 35971450
[TBL] [Abstract][Full Text] [Related]
12. Enhanced systemic exposure of fexofenadine via the intranasal administration of chitosan-coated liposome.
Qiang F; Shin HJ; Lee BJ; Han HK
Int J Pharm; 2012 Jul; 430(1-2):161-6. PubMed ID: 22525082
[TBL] [Abstract][Full Text] [Related]
13. Formulation and optimization of theophylline-loaded enteric-coated spanlastic nanovesicles for colon delivery; Ameliorate acetic acid-induced ulcerative colitis.
Barakat EH; Akl MA; Ibrahim MF; Mohamed Dawaba H; Afouna MI
Int J Pharm; 2023 Aug; 643():123253. PubMed ID: 37473974
[TBL] [Abstract][Full Text] [Related]
14. Gastrointestinal stability, physicochemical characterization and oral bioavailability of chitosan or its derivative-modified solid lipid nanoparticles loading docetaxel.
Shi LL; Lu J; Cao Y; Liu JY; Zhang XX; Zhang H; Cui JH; Cao QR
Drug Dev Ind Pharm; 2017 May; 43(5):839-846. PubMed ID: 27487431
[TBL] [Abstract][Full Text] [Related]
15. Lipid nanoparticles coated with chitosan using a one-step association method to target rifampicin to alveolar macrophages.
Vieira ACC; Chaves LL; Pinheiro M; Lima SC; Neto PJR; Ferreira D; Sarmento B; Reis S
Carbohydr Polym; 2021 Jan; 252():116978. PubMed ID: 33183580
[TBL] [Abstract][Full Text] [Related]
16. Chitosan-Coated Solid Lipid Nanoparticles as an Efficient Avenue for Boosted Biological Activities of
Aldayel TS; M Badran M; H Alomrani A; AlFaris NA; Z Altamimi J; S Alqahtani A; A Nasr F; Ghaffar S; Orfali R
Molecules; 2023 Apr; 28(8):. PubMed ID: 37110803
[No Abstract] [Full Text] [Related]
17. Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis.
Xiao B; Xu Z; Viennois E; Zhang Y; Zhang Z; Zhang M; Han MK; Kang Y; Merlin D
Mol Ther; 2017 Jul; 25(7):1628-1640. PubMed ID: 28143741
[TBL] [Abstract][Full Text] [Related]
18. Chitosan-coupled solid lipid nanoparticles: Tuning nanostructure and mucoadhesion.
Sandri G; Motta S; Bonferoni MC; Brocca P; Rossi S; Ferrari F; Rondelli V; Cantù L; Caramella C; Del Favero E
Eur J Pharm Biopharm; 2017 Jan; 110():13-18. PubMed ID: 27989765
[TBL] [Abstract][Full Text] [Related]
19. Systematically designed chitosan-coated solid lipid nanoparticles of ferulic acid for effective management of Alzheimer's disease: A preclinical evidence.
Saini S; Sharma T; Jain A; Kaur H; Katare OP; Singh B
Colloids Surf B Biointerfaces; 2021 Sep; 205():111838. PubMed ID: 34022704
[TBL] [Abstract][Full Text] [Related]
20. Formulation and biopharmaceutical evaluation of risperidone-loaded chitosan nanoparticles for intranasal delivery.
Rukmangathen R; Yallamalli IM; Yalavarthi PR
Drug Dev Ind Pharm; 2019 Aug; 45(8):1342-1350. PubMed ID: 31094571
[No Abstract] [Full Text] [Related]
[Next] [New Search]
